novo nordisk new glp 1 promotes GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article Novo Nordisk Reports Positive Test

A new Australian meta-analysis of more than 85,000 patients, including those with and without diabetes, found GLP-1 receptor agonists reduced the risk of kidney failure by 16%, and the worsening of kidney function by 22%

Both effects respond to morning dosing and dose reduction to 250 mcg

In the future, they plan to study whether using Melanotan II outside the central nervous system would deliver similar results

Among NSAIDs, diclofenac has one of the higher cardiovascular (CV) risk profiles, including increased risk of hypertension, myocardial infarction, and stroke

Share: The growing popularity of GLP-1 medications such as Ozempic, Wegovy, and Rybelsus has largely been driven by their ability to help people lose weight, improve blood sugar control, and reduce the risk of cardiovascular disease

Cell 90 , 11071112 (1997)